Relationship between MPVLR and Clinical Characteristics and Prognosis of Advanced Lung Cancer Patients with Platinum Chemotherapy
Objective To explore the relationship between the mean platelet volume to lymphocyte ratio ( MPVLR ) and both clinical manifestations and platinum-based chemotherapy prognosis in patients with advanced lung cancer.Methods Ninety patients with advanced lung cancer who underwent platinum-based chemotherapy at Anhui Wannan Rehabilitation Hospital between March 2019 and February 2022 were selected as study subjects.Receiver operating characteristic ( ROC ) curves were plotted to determine MPVLR cutoff values,and patients were subsequently divided into a low MPVLR group ( MPVLR<4.72,n=52 ) and a high MPVLR group ( MPVLR ≥ 4.72,n=38 ) .Chi-square tests were employed to analyze the association between MPVLR levels and clinical manifestations in these patients.Kaplan-Meier survival analysis was conducted,and multivariate Cox regression analysis was utilized to investigate the factors influencing platinum-based chemotherapy prognosis in advanced lung cancer.Results The area under the ROC curve ( AUC ) for MPVLR in predicting the prognosis of platinum-based chemotherapy in advanced lung cancer patients was 0.872 ( 95％ CI:0.820-0.925 ),with a cutoff value of 4.72,specificity of 0.659,and sensitivity of 0.912.The high MPVLR group exhibited a higher proportion of clinical stage Ⅳ,tumor diameter>5 cm,distant metastasis,and pleural effusion compared to the low MPVLR group,with statistically significant differences ( P<0.05 ) .Kaplan-Meier survival analysis revealed that patients with clinical stage Ⅳ,tumor diameter>5 cm,distant metastasis,and MPVLR ≥ 4.72 had a significantly shorter median survival time compared to those with clinical stage Ⅲ,tumor diameter ≤ 5 cm,no distant metastasis,and MPVLR<4.72 ( P<0.05 ) .Multivariate Cox regression analysis indicated that clinical stage Ⅳ ( HR=2.143,95％ CI:1.459-3.146 ),distant metastasis ( HR=2.408,95％ CI:1.602-3.621 ),and MPVLR ≥ 4.72 ( HR=2.726,95％ CI:1.792-4.147 ) were independent risk factors for the prognosis of platinum-based chemotherapy in advanced lung cancer patients ( P<0.05 ) .Conclusion Elevated MPVLR levels are associated with clinical stage,tumor diameter,distant metastasis,and pleural effusion in patients with advanced lung cancer and can serve as an important marker for predicting the prognosis of these patients undergoing platinum-based chemotherapy.
Mean platelet volume/lymphocyte ratioLung tumorsPlatinum compoundsChemotherapyPrognosisROC curveArea under the curve ( AUC )Regression analysis
万方数据
维普
